Last year, biotech excelled in terms of financing, but failed to set the stock markets alight. Total biotech financing surpassed 2000 levels to reach $46 billion, although much of this came from partnership deals where payments may (or may not) extend into the future. Debt deals led all categories, almost doubling over 2005, whereas private investment in public equity (PIPEs) increased by more than half.
Source: Multex, BioCentury
Source: BioCentury, Burrill & Company
Source: BioCentury
Source: BioCentury
Source: BioCentury, Recombinant Capital
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Lawrence, S. A stellar year for financing. Nat Biotechnol 25, 156 (2007). https://doi.org/10.1038/nbt0207-156
Issue Date:
DOI: https://doi.org/10.1038/nbt0207-156
